Table 2.
Frequencies of genetic variants associated with HF pharmacotherapy response
| GENE | VARIANT | rsID | MINOR ALLELE | CAUCASIAN | AFRICAN-AMERICANS |
|---|---|---|---|---|---|
| ABCB1 | C3435T | rs1045642 | C | 45% | 87% (Africans) |
| ACE | Ins/Del Intron 16 | rs1799752 | Ins | 44% | 43% |
| ADD1 | Gly460Trp | rs4961 | Trp | 17% | 11% |
| ADRA1D | T1848A | rs2236554 | A | 46% | 12% (Africans) |
| A1905G | rs709024 | A | 38% | 70% (Africans) | |
| ADRA2C | Ins/Del 322-325 | rs61767072 | Del | 4% | 43% |
| ADRB1 | Ser49Gly | rs1801252 | Gly | 17% | 25% |
| Arg389Gly | rs1801253 | Gly | 27% | 38% | |
| ADRB2 | Gly16Arg | rs1042713 | Arg | 40% | 50% (Africans) |
| Gln27Glu | rs1042714 | Glu | 42% | 20% | |
| Thr164Ile | rs1800888 | Ile | 2% | <2% (Africans) | |
| AGTR1 | A1166C | rs5186 | C | 25% | 5% |
| ANP | Val32Met | rs5063 | Met | 4% | 2% |
| Ter152Arg | rs5065 | Ter | 14% | 43% (Africans) | |
| CYP11B2 | T-344C | rs1799998 | C | 43% | 30% |
| CYP2C9 | *2 | N/A | N/A | 14% | <1% |
| *3 | N/A | N/A | 11% | <1% | |
| EDN1 | G/A (IVS)-4 | rs2071942 | A | 29% | 17% (Africans) |
| Lys198Asn | rs5370 | Asn | 30% | 17% | |
| GNB3 | C825T | rs5443 | T | 39% | 91% (Africans) |
| GRK5 | Gln41Leu | rs17098707 | Leu | 2% | 24% |
| NET | T-182C | rs2242446 | C | 25% | 15% (Africans) |
| NOS3 | Glu298Asp | rs1799983 | Asp | 22% | 7% (Africans) |
| SCNN1B | Most frequent haplotype | N/A | n/a | 65% | n/a |
| SCNN1G | C4G | rs5723 | G | 28% | 24% (Africans) |
| SLC12A3 | Gly264Ala | rs1529927 | Ala | 8% | <1% (Africans) |